A new report from Partnership for Health Analytic Research or PHAR describes how value assessments that use traditional cost-effectiveness analyses can overlook important health disparities and risk perpetuating health inequities.
These analyses, also known as CEAs, frequently are the basis for value assessments such as those performed by the Institute for Clinical and Economic Review (ICER) and other assessment organizations to evaluate the value of medicines and other tests and treatments. But using traditional cost-effectiveness analyses in coverage decisions can hinder progress toward an equitable U.S. health care system by failing to account for important differences among different patient groups. Here are two things you should know from the report.
- Traditional CEAs ignore health disparities by overlooking patient differences. Traditional cost-effectiveness analyses use a population-wide average risk of disease, treatment utilization and therapy efficacy to judge care “value.” The prevalence or risk of disease in different groups can change the value of a treatment for that group, but traditional CEA ignores these differences. The risk of breast cancer disease in women ranges from 8% in American Indians and Alaskan Natives to 12% in Black Americans. Over the past two years, women over the age of 40 who had mammograms ranged from nearly 58% of Asians to 67% of white Americans. The significant nuances between health and treatment experiences across various demographics are not accounted for using general population averages within CEAs. This presents the potential risk of harmful bias on patient health outcomes.
- This type of value assessment often undervalues treatments for certain populations. CEAs that rely on the quality-adjusted life year, or QALY, can devalue the lives of patients, particularly those who already experience health inequities like patients from communities of color and patients with disabilities. For instance, the COVID-19 pandemic has widened the life expectancy disparity between white and Black adults. When considering an intervention that can reverse a fatal condition, less value could be assigned to a treatment given to a Black patient than a white patient because of this difference in life expectancy. That’s not right.
Supporting a more affordable, sustainable health care system for all patients is essential. So is making sure the tools we use to do this reduce health disparities rather than reinforce them. To learn more about PhRMA’s efforts to improve value assessment frameworks and health equity, visit PhRMA.org/Value-Collaborative.
Jackie McRae
is a Director of Policy, Research, and Membership at PhRMA focusing on health equity and the value of medicines. Jackie graduated with a Doctorate of Pharmacy from Mercer University and Master of Science in Applied Health Economics and Outcomes Research from Thomas Jefferson University. Jackie previously worked as a Post-Doctoral Fellow in Health Economics and Outcomes Research at Janssen Scientific Affairs and Thomas Jefferson University. Outside the office, Jackie can be found hiking on local trails and enjoying scenic drives.
Jackie McRae
Recent events highlight progress on health equity
ICYMI: PhRMA’s 4th Annual Pathways to Success: Virtual STEM Career Expo
Hispanic Heritage Month: Fighting for Hispanic patients
PhRMA awards grants to 2024 Annual Pathways to Success: Virtual STEM Career Expo Partners
How government price setting fails to address systemic health care inequities
Women’s Health Month: A conversation with Sage
Championing cancer equity: Our drive for healthier AANHPI communities
New analysis: Accelerated approval pathway is changing lives in underserved communities
New analysis: Flawed assessments of a medicine’s value jeopardize patient access
PhRMA provides grant funding to support the Morehouse School of Medicine Satcher Health Leadership Institute’s Health Equity Tra
New social determinants of health simulation explores structural barriers patients face accessing and affording medicines
PhRMA awards grants to 2023 Annual Pathways to Success Graduate Summit Partners
Between hope and despair: Improving cancer outcomes
PhRMA awards grant to Emerson Diversity Health Foundation
PhRMA Otorga Beca a la “Emerson Diversity Health Foundation”
Using traditional HTAs to determine coverage threatens patient access to medicine
Traditional HTAs keep diverse patients out of the conversation
How HTA-based price controls could worsen health outcomes and health disparities
Traditional HTA methods treat everyone like the “average” patient
Value assessment should include all aspects of value that matter to patients
Potential gene therapies bring hope to patients with sickle cell disease
PhRMA presents research at ISPOR 2022
Stephanie Dyson of BMS on reducing health disparities
Sharing rebates can save Americans with diabetes 500 each year and improve adherence
Announcing CAREs Grant Round 4
Announcing CAREs Grant Round 4
Guest Series: PhRMA talks racial and health equity with Lauren Powell, VP US Health Equity and Community Wellness, Takeda
PhRMA awards $75,000 to fund initiatives to reduce health inequities
Watch: Building trust and enhancing clinical trial diversity
More than 800 medicines are in development for diseases that disproportionately affect racial and ethnic communities
PhRMA hosts first stakeholder workshop on clinical trial diversity
Creating a new patient risk paradigm in American health care
Study finds nearly half of payers believe innovative contracts can lead to lower patient out-of-pocket costs
PhRMA CAREs Grant request for proposals: Addressing inequities in access to COVID-19 testing, therapeutics and vaccines
PhRMA member companies share how they are improving clinical trial diversity
Guest post: PhRMA talks racial and health equity with Stephanie Dyson, Head of Office at Biogen
Paper finds gaps in health data are a barrier to health equity
New research shows hotspots of inequity relate to increased COVID-19 hospitalizations
Increasing diversity at investigator sites could increase minority participation in clinical trials
Report highlights biopharmaceutical industry’s commitment to D&I
Strengthening a culture dedicated to patients and equity: A conversation with Percival Barretto-Ko, President of Astellas US
PhRMA CAREs Grant request for proposals: Addressing racial disparities in medication utilization and adherence
Committing to diversity, equity and inclusion: A call to action for clinical trials
Just released: PhRMA members’ new clinical trial diversity principles
ICYMI: Addressing health inequities: Biopharmaceutical companies are rising to the occasion
Guest Post: Honoring Hispanic Heritage Month by taking action on health equity
Sharing rebates can improve access to medicines and increase health equity
Growth in innovative, value-based contracts holds promise for the health system and for patients
PhRMA will continue to advocate for equity within our industry
Innovative contracts drive access for patients and value for the system
Three ways the pharmaceutical industry can positively impact health equity
Guest Post: Amgen Foundation stands for equal opportunities in STEM learning
Systemic racism is as real as any disease, and our industry is not immune
Guest Post: Pride started with protest: Combatting the dual pandemics of COVID-19 and racism this Pride Month
PhRMA awards $100,000 to fund projects that address health inequalities
Observing National Minority Health Month in the age of COVID-19
ICYMI: Patients saved nearly $800,000 out of pocket through innovative contracting arrangements
Low-value health care costs $345B each year and provides little benefit
Addressing barriers that inhibit value-based contracts
Guest post: Value-based agreements can improve outcomes and even save patients money at the pharmacy counter
New data show how ICER’s value framework could prevent or delay access to treatments for Medicaid patients across the country
5 Ways to improve ICER’s value assessment framework
Assessing value top of mind at ISPOR 2019
New analysis shows 820,000 prescriptions would be in jeopardy if ICER’s value framework is used in Medicaid
Value assessments should include all the outcomes that matter to patients and families
Event tomorrow: Leaders convene to discuss solutions to advance value-driven health care
New whitepaper identifies reasons why ICER’s cost-effectiveness analyses are not useful for payers
Guest post: Developing new payment models to ensure patients have access to high-investment therapies
Number of value-based contracts continues to rise
ICER’s budget impact threshold: Sounding a false alarm on affordability and access
PhRMA submission to HHS on blueprint to lower drug prices and reduce out-of-pocket costs
How ICER’s assessment of a new class of migraine treatments fails patients
Aspen Spotlight Health: Discussing the forefront of innovation
New analysis shows negative impact of ICER’s value framework on patient access in Medicare Part B
ICYMI: Recent survey adds to growing body of research on barriers to innovative payment approaches
Reality check: Value-based contracts are good for patients
Video: Barriers to results-based contracts
Improving care quality by engaging patients in shared decision making
ICYMI: Research shows promise of innovative payment arrangements in reducing costs, improving access
Clarity around anti-kickback statute needed to promote innovative payment arrangements
Video: What is a results-based contract?
Johnson & Johnson, Pfizer, Walgreens and other CEOs discuss value in the future of health care
PhRMA CEO in Forbes - How to negotiate better deals for prescription medicines
ICYMI: Innovative payment models helping provide patient access to new medicines
RA medicines often demonstrate far greater benefits to patients than initially understood
Stakeholders Agree: Modernize the legal framework to support move to value-driven health care
How do multiple sclerosis patients define value?
PhRMA CEO talks White House meeting, innovation & jobs with POLITICO’s Pulse Check
VIDEO: PhRMA CEO discusses #GOBOLDLY campaign and White House meeting with CNNMoney’s Maggie Lake
The Value Collaborative: Advancing private market solutions to achieve better health, lower costs
You won’t fix what you don’t value: Two reasons why traditional cost-effective analyses can perpetuate health inequities
The Value Collaborative
Value Assessment
Health Equity
You won’t fix what you don’t value: Two reasons why traditional cost-effective analyses can perpetuate health inequities
You won’t fix what you don’t value: Two reasons why traditional cost-effective analyses can perpetuate health inequities